At the annual meeting of the American Association for Cancer Research (AACR), the focus has converged on the stubborn complexity of the KRAS protein — a long-time "undruggable" target that is finally beginning to yield. Revolution Medicines presented data this week on its experimental drug daraxonrasib, demonstrating a significant, if sober, step forward in the treatment of second-line pancreatic cancer. The results show that daraxonrasib more than doubled median survival compared to traditional chemotherapy, extending it by roughly six months.
In the context of pancreatic cancer, a disease notorious for its rapid progression and limited therapeutic options, such a margin is statistically meaningful. Pancreatic ductal adenocarcinoma remains among the deadliest solid tumors, with five-year survival rates that have barely shifted over decades. Most patients are diagnosed at advanced stages, and the standard second-line regimens — typically variations of fluorouracil-based chemotherapy — offer limited benefit. A drug that doubles median survival in this setting represents a genuine inflection point in the molecular targeting of the disease, even as the absolute gain underscores how far the field still has to travel.
KRAS: From Undruggable to Targetable
The KRAS gene family has been central to cancer biology since its discovery in the early 1980s. Mutations in KRAS — particularly the G12C, G12D, and G12V variants — drive a substantial share of pancreatic, colorectal, and non-small cell lung cancers. For decades, the protein's smooth, pocket-less surface made it resistant to small-molecule inhibition, earning it the label "undruggable." That consensus began to crack with the approval of sotorasib and adagrasib, both targeting the KRAS G12C mutation, primarily in lung cancer. Those drugs validated the concept but addressed only a narrow slice of KRAS-driven disease.
Daraxonrasib represents a broader approach. Rather than targeting a single mutation variant, the drug is designed to inhibit KRAS in its active, GTP-bound state across multiple mutation types — a strategy sometimes described as pan-KRAS or multi-RAS inhibition. This is particularly relevant for pancreatic cancer, where the G12D variant predominates and where earlier KRAS-targeted therapies had limited applicability. The clinical data presented at AACR suggest that this wider inhibition strategy can translate into measurable survival benefit in a tumor type that has historically resisted targeted therapy.
The result also raises a strategic question for the broader oncology pipeline. If pan-RAS inhibition proves durable across tumor types, it could reshape treatment sequencing for a range of KRAS-driven cancers, not just pancreatic. Several competitors are developing their own multi-RAS programs, and the competitive landscape is likely to intensify as more data mature.
The NCI and the Confidence Deficit
Beyond the clinical data, the AACR meeting served as a forum for institutional stabilization. The director of the National Cancer Institute addressed the assembled researchers, seeking to allay persistent anxieties regarding federal funding and the continuity of cancer research initiatives. The backdrop is familiar: biomedical research in the United States depends heavily on federal grants administered through the National Institutes of Health, of which the NCI is the largest single institute by budget. Disruptions to that funding — whether through sequestration, continuing resolutions, or political reprioritization — ripple through academic labs, clinical trial networks, and early-career researcher pipelines.
While last year's gathering was clouded by uncertainty over the political landscape, this year's tone was one of cautious pragmatism. The challenge for the NCI is not merely budgetary but psychological: sustained ambiguity about funding erodes the willingness of young scientists to enter cancer research and of institutions to commit to long-term programs. The director's remarks appeared aimed at restoring a baseline of predictability, though the structural pressures on federal science funding remain unresolved.
The juxtaposition at AACR is instructive. On one side, a drug that took decades of foundational KRAS biology to reach the clinic, delivering a hard-won six months of survival. On the other, an institutional apparatus whose stability is essential to producing the next generation of such breakthroughs but whose future funding trajectory remains uncertain. Whether the scientific infrastructure can sustain the pace of discovery that made daraxonrasib possible is a question that no single meeting — or single drug — can answer.
With reporting from STAT News.
Source · STAT News (Biotech)
